Virtual Patient Case: Carcinoid Syndrome - Best Practices and Emerging Treatment Strategies

Virtual Patient Case: Carcinoid Syndrome - Best Practices and Emerging Treatment Strategies

On-Demand Webcast
Faculty

Martyn Caplin, DM, FRCP
Professor of Gastroenterology and G.I. & Tumour Neuroendocrinology
Royal Free Hospital
London, United Kingdom

Target Audience

This educational activity is designed for medical oncologists, hematologists, general surgeons, GI internists, GI surgeons, oncology nurses, nurse practitioners, physician assistants and other healthcare professionals interested in the therapeutic management of patients with carcinoid syndrome.

Overview

As the standard of care and novel strategies for the management of carcinoid syndrome are further investigated and refined, it is essential that healthcare professionals who care for these patients are provided with guidance for the successful integration of these potentially paradigm-changing advances into their clinical practice. To this end, Carcinoid Syndrome: Best Practices and Emerging Treatment Strategies is designed to inform oncologists who manage patients with carcinoid syndrome how to safely and effectively incorporate emerging therapies into current clinical algorithms to optimally sequence treatments. This Virtual Patient Case provides the perspective of renown clinical expert Dr. Martyn Caplin on the latest advances and insights from pivotal clinical trials.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Relate the key pathophysiologic processes underlying carcinoid syndrome to current and emerging therapeutic approaches
  2. Assess the therapeutic potential of current and emerging agents designed to manage symptoms and enhance quality of life in patients with carcinoid syndrome
  3. Evaluate the benefits and risks associated with current therapies designed for the management of carcinoid syndrome, and develop an evidence-based algorithm to optimally sequence treatments
Provider

This activity is provided by Imedex®, LLC.
Imedex

Support

Supported by an educational grant from: Ipsen Innovation SAS

Disclosure

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Martyn Caplin, DM, FRCP AAA2; Ipsen Innovation SAS2; Lexicon Pharmaceuticals2; Novartis Pharmaceuticals Corporation2

All materials are included with the permission of the authors.

Imedex, LLC Staff Disclosure of Financial Relationships
All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

   Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2018 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334
Email: elearning@imedex.com

Additional Downloads

Release Date: June 29, 2018

Expiration Date: June 29, 2019